15/10/02说明:此前论坛服务器频繁出错,现已更换服务器。今后论坛继续数据库备份,不备份上传附件。

肝胆相照论坛

 

 

肝胆相照论坛 论坛 学术讨论& HBV English 评估慢性HBV患者的HCC风险(REACH,PAGE-B及更高) ...
查看: 328|回复: 1
go

评估慢性HBV患者的HCC风险(REACH,PAGE-B及更高) [复制链接]

Rank: 8Rank: 8

现金
62111 元 
精华
26 
帖子
30437 
注册时间
2009-10-5 
最后登录
2022-12-28 

才高八斗

1
发表于 2020-8-21 21:34 |只看该作者 |倒序浏览 |打印
Assessment of HCC Risk in Patients with Chronic HBV (REACH, PAGE-B, and Beyond)

    Terry Cheuk-Fung Yip, Lilian Yan Liang & Grace Lai-Hung Wong

Current Hepatology Reports volume 19, pages285–292(2020)Cite this article

    54 Accesses

    1 Altmetric

    Metrics details

Abstract
Purpose of Review

To provide an updated overview on the current status of risk prediction scores for hepatocellular carcinoma (HCC) in patients with chronic hepatitis B virus infection.
Recent Findings

More HCC risk scores have been developed, validated, and optimized (e.g., with liver stiffness measurement) in different patient and ethnic groups. Risk scores for treated patients with high negative predictive values would be able to identify patients who may not need HCC surveillance anymore as their HCC risk has been reduced by antiviral therapy.
Summary

Current HCC risk scores can accurately predict HCC in specific populations, in both treatment-naive patients and those receiving antiviral therapy. Different levels of care and different intensities of HCC surveillance should be offered according to the risk profile of patients.

Rank: 8Rank: 8

现金
62111 元 
精华
26 
帖子
30437 
注册时间
2009-10-5 
最后登录
2022-12-28 

才高八斗

2
发表于 2020-8-21 21:34 |只看该作者
评估慢性HBV患者的HCC风险(REACH,PAGE-B及更高)

    叶德丰,叶丽莲,梁丽红

《当前肝病学报告》第19卷,第285-292页(2020年)

    54次访问

    1高​​度

    指标详细信息

抽象
审查目的

提供有关慢性乙型肝炎病毒感染患者肝细胞癌(HCC)风险预测评分的当前状态的最新概述。
最近的发现

在不同的患者和种族中,已经开发,验证和优化了更多的HCC风险评分(例如,通过肝硬度测量)。具有高阴性预测值的已治疗患者的风险评分将能够确定不再需要进行HCC监测的患者,因为他们的HCC风险已通过抗病毒治疗降低了。
摘要

当前的HCC风险评分可以准确预测未接受治疗的患者和接受抗病毒治疗的患者在特定人群中的HCC。应根据患者的风险状况提供不同级别的护理和不同程度的HCC监测。
‹ 上一主题|下一主题
你需要登录后才可以回帖 登录 | 注册

肝胆相照论坛

GMT+8, 2024-11-16 04:03 , Processed in 0.020126 second(s), 11 queries , Gzip On.

Powered by Discuz! X1.5

© 2001-2010 Comsenz Inc.